Giuliano A E, Rangel D, Golub S H, Holmes E C, Morton D L
Cancer. 1979 Mar;43(3):917-24. doi: 10.1002/1097-0142(197903)43:3<917::aid-cncr2820430320>3.0.co;2-3.
Immunosuppression in 45 patients with lung cancer was studied by examining delayed cutaneous hypersensitivity reactions to DNCB and by analyzing the effect of the patient's serum on the proliferative response of normal donor lymphocytes. Both diminution of DNCB reactivity and inhibition of the proliferative response of normal donor lymphocytes to mitogens were associated with the stage of the disease and the presence of unresected tumor. Suppressive sera were associated with poor prognosis. The suppressive effects of patients' sera on lymphocytes from a normal donor suggest that the immunosuppression seen in lung cancer may be mediated by serum factors. The significant association of clinically evident tumor with this serum-mediated immunosuppression further suggests that the tumor itself could account for the appearance of these factors in the host. The clinical implications of these findings may be useful for designing new clinical trials.
通过检测对二硝基氯苯（DNCB）的迟发性皮肤过敏反应以及分析患者血清对正常供体淋巴细胞增殖反应的影响，对45例肺癌患者的免疫抑制情况进行了研究。DNCB反应性降低以及正常供体淋巴细胞对有丝分裂原的增殖反应受到抑制均与疾病分期及未切除肿瘤的存在有关。抑制性血清与预后不良相关。患者血清对正常供体淋巴细胞的抑制作用表明，肺癌中所见的免疫抑制可能由血清因子介导。临床上明显的肿瘤与这种血清介导的免疫抑制之间的显著关联进一步表明，肿瘤本身可能是宿主中这些因子出现的原因。这些发现的临床意义可能有助于设计新的临床试验。
